A bee ingestible composition comprising a bee food base and THC and/or CBD is provided. Also provided are methods of producing honey, honey obtainable by these methods and uses of same.

The present invention is directed to a palatable soft chew veterinary composition comprising at least one active agent, at least one binding agent, at least one disintegrant, at least one wetting agent, and at least one flavorant, and methods for controlling or treating a condition in an animal comprising administering the composition to said animal in need thereof.

Pharmaceutical compositions are provided, which comprise effective amounts of an opioid analgesic such as oxycodone, and an antiemetic, such as promethazine, to treat a subject for conditions, including for reducing or eliminating an adverse effect associated with the opioid analgesic.

Novel compounds of Formula I ##STR00001##
and their use in therapeutic treatments.

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.

Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Pharmaceutical compositions are provided which comprise effective amounts of an analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.